Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Revance Therapeutics (RVNC)

$16.20 0.26 (1.63%)

17:05 EST RVNC Stock Quote Delayed 15 Minutes

Volume:

Previous Close $16.20

Market Cap 595.90M

PE Ratio -4.01

EPS -4.04

Volume (Avg. Vol.) 372,491

Day's Range 15.89 - 16.28

52-Week Range 9.88 - 24.99

Dividend & Yield N/A (N/A)

RVNC Stock Predictions, Articles, and Revance Therapeutics News

From InvestorPlace
From the Web

10 Monster Growth Stocks to Buy for 2019 and Beyond

By Harriet Lefton, Writer, TipRanks Oct 31, 2019

These 10 monster growth stocks to buy all offer exciting opportunities. There's the important information for investors to keep in mind.

Revance Therapeutics Inc Is Set to Shake Up the Botox Market

By Chris Lau, InvestorPlace Contributor Apr 4, 2018

RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.

Revance Therapeutics (RVNC) Received its Third Buy in a Row

From Smarter Analyst Nov 14, 2019

After Mizuho Securities and Needham gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from

Revance Therapeutics (RVNC) Q3 2019 Earnings Call Transcript

From The Motley Fool Nov 5, 2019

RVNC earnings call for the period ending September 30, 2019.

Revance Therapeutics (RVNC) Received its Third Buy in a Row

From Smarter Analyst Nov 5, 2019

After Mizuho Securities and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time

Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (NASDAQ: RVNC) and Celgene (NASDAQ: CELG)

From Analyst Ratings Nov 5, 2019

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report) and Celgene (CELG – Research Report). Revance Therapeutics (RVNC) In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Revance Therapeutics, with a price target of $34.00.

Revance Therapeutics EPS beats by $0.02, misses on revenue

From Seeking Alpha Nov 4, 2019

Revance Therapeutics (NASDAQ:RVNC): Q3 GAAP EPS of -$0.96 beats by $0.02.Revenue of $0.05M (-97.9% Y/Y) misses by $0.37M.Cash and equivalents of $58.92MPress Release

10 Monster Growth Stocks to Buy for 2019 and Beyond

From InvestorPlace Oct 31, 2019

These 10 monster growth stocks all offer exciting opportunities. There's the important information for investors to keep in mind.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

D

Sell

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!